Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

Contributed by: PR Newswire

Tags

Rona-Therapeutics

More Like This

Rona Therapeutics Announces IND Filing of RN3161, a Highly Potent and Durable INHBE siRNA for Obesity

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms

PR Newswire associated0

Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development

Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

Rona Therapeutics Announces Breakthrough Data on Potential Annual Dosing RNAi Therapy RN026 Targeting Lipoprotein(a) in The National Lipid Association (NLA) Scientific Sessions 2025

PR Newswire associated0

Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction

Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions